CoreMine™ VITAE

EP PERMED JTC2027 · CELL & GENE THERAPY FOR PERSONALISED MEDICINE

AI and bioinformatics for personalised cell & gene therapy

Your data and AI partner for patient stratification, target design and response prediction.

Maria Mastrangelopoulou, MSc, PhD

CEO · Coremine Vitae AS · Oslo, Norway maria@coreminevitae.com

CoreMine™

ABOUT US

About Coremine Vitae

A Norwegian health-tech SME specialising in AI, bioinformatics and multimodal biomedical data.

We bridge research and data with real-world decisions, turning complex biomedical evidence into clear, actionable outputs for healthcare, research and patients. We build on the PubGene heritage in biomedical text mining and knowledge extraction.

ORGANISATION

Coremine Vitae AS · Oslo, Norway

LEGAL STATUS

SME · PIC 938247827

NATIONAL FUNDER

Research Council of Norway

CoreMine™

EXPERTISE

Where biomedicine, data and AI meet

Data harmonisation

FAIR, interoperable clinical and molecular data

Omics & biomarkers

Genomics, proteomics and metabolomics analysis

AI & machine learning

Predictive models, RAG and domain-adapted LLMs

Decision support

Dashboards and portals used in real workflows

Predictive analytics

Treatment-response and risk prediction

Evidence synthesis

Literature mining and knowledge extraction

Personalised medicine

200+ personalised reports delivered

Science & patient comms

Evidence-based writing and health-literacy portals

CoreMine™

TECHNOLOGY

Platforms we bring to the project

01

Coremine Platform

Literature mining and integrated knowledge bases, shown as visual networks of biological relationships.

02

Data-to-peptide pipeline

Translates patient genomic data into candidate peptides for personalised immunotherapy.

03

AI development framework

Neural networks, autoencoders and LLM fine-tuning for domain-specific biomedical tasks.

CoreMine™

OUR ROLE IN JTC2027

What we bring to a cell & gene therapy consortium

Patient stratification

Multi-omics and AI to select the patients most likely to benefit

Target & peptide design

Data-to-peptide pipeline for personalised immunotherapy

Response & safety prediction

Predictive models linking clinical and molecular data

Evidence & knowledge mining

Literature and network analysis to support the rationale

FAIR data work packages

Harmonisation, interoperable workflows and data management

Patient engagement

Health-literacy content and patient-facing communication

CoreMine™ VITAE

PROVEN DELIVERY

Already trusted by EP PerMed

EP PERMED JTC2026 · SELECTED FOR FUNDING

HARMONIA

Personalised prediction of cardiovascular and kidney complications in MASLD, combining molecular and clinical data, AI and digital-twin approaches.

200+

personalised medicine reports combining evidence synthesis and clinical input

Hjernesvulstportalen

Brain-cancer patient portal, launched 2025 with the Norwegian Brain Cancer Association

CoreMine™

TRACK RECORD

Two decades of EU and national projects

Years	Project · programme	Focus
2026	GLIO-ODYSSEY · Horizon Cancer Mission	Virtual human twins for glioblastoma (submitted)
2022–2025	ANTISeptic · Eurostars	Mass-spec detection of antimicrobial resistance
2021–2024	Coremine Vitae Project · RCN	Personalised treatment options in cancer
2021–2024	Pathobody · Eurostars	Proteogenomic antibody pipeline
2016–2020	Glioma Strategies · Eurostars	Bioinformatics and phosphoproteomics
2016–2018	Precision Cancer Medicine Services · Eurostars	Coordinator · precision oncology services
2012–2015	GenomeMiner · RCN	Personalised oncology software
2004–2008	DIAMONDS · EU FP6	Systems biology integration

CoreMine™ VITAE

Let’s build your JTC2027 consortium

We welcome academic, clinical and industry partners looking for AI and bioinformatics work packages, data harmonisation, biomarker analytics and predictive modelling.

Maria Mastrangelopoulou, MSc, PhD
CEO · Coremine Vitae AS · SME · Oslo, Norway

maria@coreminevitae.com
www.coreminevitae.com · +47 97 61 99 48